Edit |   |
---|---|
Antigenic Specificity | CALCRL/CGRP-R (Erenumab biosimilar) |
Clone | monoclonal |
Host Species | Recombinant Human |
Reactive Species | human |
Isotype | IgG2 lambda |
Format | Protein A/G purified |
Size | 100 µg, 1 mg, |
Concentration | typically between 0.5-2.0 mg/ml. |
Applications | ELISA, WB |
Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
Description | Erenumab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CALCRL/CGRP-R, for use in laboratory research applications. This product is not suitable for use as medicines or in human, therapeutic or diagnostic applications. Erenumab (AMG-334) (INN; trade name Aimovig) is a human monoclonal antibody designed specifically to bind and antagonize the calcitonin gene-related peptide receptor (CGRPR) as a means to prevent migraines. Aimovig, as released and marketed by Novartis and Amgen, is in fact a novel therapeutic approach as the first and only FDA approved treatment specifically developed to prevent migraine by blocking the CGRP receptor, which is believed to play a critical role in migraine. |
Immunogen | n/a |
Other Names | Erenumab, CALCRL/CGRP-R, 1582205-90-0 |
Gene, Accession # | CAS: 1582205-90-0 |
Catalog # | abx831384 |
Price | please inquire |
Order / More Info | CALCRL/CGRP-R (Erenumab biosimilar) Antibody from ABBEXA LTD |
Product Specific References | n/a |
U.S. Office
118 Eldridge Rd, Suite C,
Sugar Land, TX 77478 USA
Telephone: +1 832 327 7413
Netherlands Office
Abbexa BV
Wattstraat 54 2723 RD,
Zoetermeer,Netherlands
Telephone: +44 (0) 1223 755950